1 |
Kuroki L, Guntupalli SR.Treatment of epithelial ovarian cancer [J].BMJ, 2020, 371: m3773.
|
2 |
Lheureux S, Braunstein M, Oza AM.Epithelial ovarian cancer:evolution of management in the era of precision medicine [J].CA Cancer J Clin, 2019, 69(4): 280-304.
|
3 |
Li Y, Zhao X, Zhou Y, et al.Decision tree model for predicting ovarian tumor malignancy based on clinical markers and preoperative circulating blood cells [J].BMC Med Inform Decis Mak, 2025, 25(1):94.
|
4 |
Hiett AK, Sonek JD, Guy M, et al.Performance of IOTA Simple Rules, Simple Rules risk assessment, ADNEX model and O-RADS in differentiating between benign and malignant adnexal lesions in North American women [J].Ultrasound Obst Gyn, 2022, 59(5): 668-676.
|
5 |
王稳, 王兴国, 刘淑娟, 等.交界性卵巢肿瘤诊治中国专家共识(2022 年版) [J].中国实用妇科与产科杂志, 2022, 38(12): 1185-1194.
|
6 |
Moro F, Vagni M, Tran HE, et al.Radiomics analysis of ultrasound images to discriminate between benign and malignant adnexal masses with solid morphology on ultrasound [J].Ultrasound Obst Gyn, 2023,65 (3): 353-363.
|
7 |
陈小军, 陈小祥, 高庆蕾, 等.卵巢癌早期筛查中国专家共识(2025年版) [J].中国实用妇科与产科杂志, 2025, 41(2): 204-211.
|
8 |
Felder M, Kapur A, Gonzalez-Bosquet J, et al.MUC16 (CA125):tumor biomarker to cancer therapy, a work in progress [J].Mol Cancer,2014, 13(4): 129-135.
|
9 |
Lycke M, Ulfenborg B, Malchau Lauesgaard J, et al.Consideration should be given to smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics [J].Clin Chem Lab Med, 2021, 59(12): 1954-1962.
|
10 |
刘春, 李媛, 朱熠, 等.探讨多模态超声诊断卵巢GI-RADS 4 类肿块的价值 [J].中国超声医学杂志, 2022, 38(4): 414-417.
|
11 |
Andreotti RF, Timmerman D, Strachowski LM, et al.O-RADS US risk stratification and management system: a consensus guideline from the ACR Ovarian-Adnexal Reporting and Data System Committee [J].Radiology, 2020, 294(1): 168-185.
|
12 |
Yoeli-Bik R, Abramowicz JS, Wroblewski K, et al.O-RADS US version 2022 improves patient risk stratification when compared with O-RADS US version 2019 [J].Radiology, 2023, 314(3): e242200.
|
13 |
Lee S, Lee JE, Hwang JA, et al.O-RADS US: a systematic review and meta-analysis of category-specific malignancy rates [J].Radiology,2023, 308(2): e223269.
|
14 |
中国医师协会超声医师分会.中国妇科超声检查指南(2017 版)[M].北京: 人民卫生出版社出版, 2017: 64-86
|
15 |
伍丽娟, 苏巧媛, 罗慧.超声O-RADS 在不同级别医师间诊断效能及一致性比较 [J].医学影像学杂志, 2025, 35(4): 106-109.
|
16 |
刘鑫, 周安艳, 胡蓉.超声O-RADS 4 亚分类联合CA125、HE4及RMI 4 预测卵巢-附件肿块恶性风险 [J].中国医学影像技术,2024, 40(10): 1548-1551.
|
17 |
李琴, 赵薇, 向秀艳, 等.基于简化流程图的O-RADS 分类系统诊断附件肿瘤良恶性的应用价值 [J].中国现代医学杂志, 2023,33(18): 59-66.
|
18 |
董虹美, 张晓航, 王希, 等.PDSA 循环在胎儿大脑中动脉超声检查质量控制中的应用 [J/OL].中华医学超声杂志(电子版), 2021,18(7): 657-663.
|
19 |
刘芳欣, 王洲, 李健, 等.超声O-RADS 分类联合超声造影及血清CA125 和HE4 检测诊断绝经后卵巢肿物的应用价值 [J].实用肿瘤杂志, 2023, 38(4): 392-397.
|